Mesoblast Limited
MESOHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeMesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. At a $1.88B market cap, Mesoblast Limited ranks as a small-cap company within healthcare. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Market Cap
$1.88B
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-207.43
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.07
ROE
-18.2%
ROA
-6.2%
Cash
$130.0M
Total Debt
$135.1M
Free CF
-$69.4M
52W Change
26.7%
Annual Financials
Cash vs Debt
The company holds $130.0M in cash, though total debt stands at $135.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$69.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $10.2M to $17.2M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mesoblast Limited's trajectory.